Abstract

Chronic kidney disease (CKD) is a condition of decreased kidney function due to chronic and irreversiblerenal parenchymal damage. Chronic kidney disease is one of the world’s health problems due to itshigh prevalence of the disease, increasing morbidity and mortality rates and expensive treatment costs.Cardiovascular complications have been recognized as the leading cause of death in CKD. Left ventricularhypertrophy (LVH), systolic and diastolic dysfunction are the most common cardiovascular complicationsfound in CKD. NTproBNP is an early diagnostic and prognostic biomarker of cardiovascular diseases,hence it can distinguish between acute and chronic cardiovascular diseases. Therefore, this examination isrecommended to monitor patient treatment. NTproBNP levels circulating in the circulations of cardiovascularpatients are about six times higher than other biomarkers including BNP. This study aims to assess serumNTproBNP levels in various degrees of CKD. This research is an observational analytic study with crosssectional approach. It was conducted between June and August 2019 at Dr. Wahidin Sudirohusodo hospitalwith total sample of 86 patients diagnosed with CKD who met the inclusion and exclusion criteria. Basedon the Kruskal Wallis test, which were used due to abnormal data distribution, a significant difference wasfound in serum NTProBNP levels based on the degree of CKD with the initial increase occured in grade IIICKD with mean value of 4,653 ng/L. Serum NTproBNP levels were not significantly different based on thedegree of hypertension. Serum NTProBNP levels were significantly correlated with urea and creatinin levelsand GFR value based on the Rho Spearman correlation test with a p value <0.05.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call